StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Equities researchers at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Separately, Dawson James began coverage on Tonix Pharmaceuticals in a report on Wednesday, February 28th. They issued a “buy” rating and a $3.00 price target on the stock.

Tonix Pharmaceuticals Price Performance

NASDAQ TNXP opened at $0.16 on Friday. The stock’s 50 day moving average is $0.29 and its 200 day moving average is $0.39. The company has a current ratio of 2.53, a quick ratio of 1.81 and a debt-to-equity ratio of 0.06. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $3.31. The stock has a market cap of $13.52 million, a PE ratio of -0.02 and a beta of 2.21.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.86) EPS for the quarter. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million. Research analysts predict that Tonix Pharmaceuticals will post -3.71 EPS for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in TNXP. JPMorgan Chase & Co. increased its stake in Tonix Pharmaceuticals by 36.9% in the 1st quarter. JPMorgan Chase & Co. now owns 285,321 shares of the company’s stock worth $66,000 after acquiring an additional 76,935 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Tonix Pharmaceuticals by 18.4% in the 1st quarter. Bank of New York Mellon Corp now owns 1,321,327 shares of the company’s stock worth $305,000 after acquiring an additional 205,428 shares during the last quarter. BlackRock Inc. increased its stake in Tonix Pharmaceuticals by 12.3% in the 1st quarter. BlackRock Inc. now owns 34,392,362 shares of the company’s stock worth $7,916,000 after acquiring an additional 3,760,804 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Tonix Pharmaceuticals by 14.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,248,831 shares of the company’s stock worth $288,000 after acquiring an additional 161,099 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Tonix Pharmaceuticals by 7.8% during the 1st quarter. Northern Trust Corp now owns 4,139,924 shares of the company’s stock valued at $952,000 after purchasing an additional 300,199 shares during the last quarter. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.